

	2007	2008	2009	2010	2011	2012	2013
Revenue			\$2,500,000.00	\$12,500,000.00	\$25,000,000.00	\$75,000,000.00	\$125,000,000.00
COGS			\$1,406,250.00	\$7,031,250.00	\$7,750,000.00	\$23,250,000.00	\$38,750,000.00
GROSS PROFIT			1,093,750.00	5,468,750.00	17,250,000.00	51,750,000.00	86,250,000.00
Operating Expense							
Direct Product Expense							
Marketing		350,000.00	500,000.00	750,000.00	775,000.00	790,000.00	810,000.00
Clinical Trials	600,000.00	650,000.00	750,000.00				
Regulatory	150,000.00	150,000.00	35,000.00	35,000.00			
R&D	500,000.00	545,000.00	484,505.00	403,630.00	358,820.00	398,290.00	442,102.00
General Admin	200,000.00	270,000.00	445,500.00	926,640.00	1,788,415.00	3,397,988.00	6,116,378.00
Total Expenses	1,450,000.00	1,965,000.00	2,215,005.00	2,115,270.00	2,922,235.00	4,586,278.00	7,368,480.00
EBIDTA	-1,450,000.00	-1,965,000.00	-1,121,255.00	3,353,480.00	14,327,765.00	47,163,722.00	78,881,520.00
				670,696.00	2,655,553.00	9,432,744.00	15,776,304.00
EBIT	-1,450,000.00	-1,965,000.00	-1,121,255.00	2,682,784.00	11,672,212.00	37,730,978.00	63,105,216.00
Tax				804,835.00	3,501,663.00	11,319,293.00	18,931,564.00
Net Income	-1,450,000.00	-1,965,000.00	-1,121,255.00	1,877,949.00	8,170,549.00	26,411,685.00	49,173,652.00

* Revenue is based on sales of the IC3 @ \$5000 per unit.